Ultragenyx Pharmaceutical Inc. (RARE)
Automate Your Wheel Strategy on RARE
With Tiblio's Option Bot, you can configure your own wheel strategy including RARE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RARE
- Rev/Share 6.7339
- Book/Share -0.7307
- PB -28.1094
- Debt/Equity -15.95
- CurrentRatio 2.4766
- ROIC -0.4359
- MktCap 2171710078.0
- FreeCF/Share -4.7247
- PFCF -4.6011
- PE -3.9079
- Debt/Assets 0.8329
- DivYield 0
- ROE -10.2442
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | RARE | Wells Fargo | -- | Overweight | -- | $65 | Oct. 20, 2025 |
| Resumed | RARE | H.C. Wainwright | -- | Buy | -- | $80 | July 28, 2025 |
| Initiation | RARE | William Blair | -- | Outperform | -- | -- | May 28, 2025 |
News
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2024 Earnings Call Transcript
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Joshua Higa - VP, IR Emil Kakkis - CEO and President Erik Harris - CCO Howard Horn - CFO Eric Crombez - CMO Conference Call Participants Tazeen Ahmad - Bank of America Salveen Richter - Goldman Sachs Gena Wang - Barclays Yaron Werber - TD Cowen Joon Lee - Truist Securities Jeff Hung - Morgan Stanley Rick Miller - Cantor Fitzgerald Luca Issi - RBC Capital Liisa Bayko - Evercore ISI Operator Good afternoon, and welcome to the Ultragenyx Fourth Quarter and …
Read More
Ultragenyx (RARE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
2024 Total Revenue of $560 million, exceeding guidance Crysvita® revenue of $410 million and Dojolvi® revenue of $88 million
Read More
About Ultragenyx Pharmaceutical Inc. (RARE)
- IPO Date 2014-01-31
- Website https://www.ultragenyx.com
- Industry Biotechnology
- CEO Emil D. Kakkis
- Employees 1294